Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
Vomiting episode; Case reference number US-BN-2025-001062 is a spontaneous case initially received from nurse via Communication (reference number: USBAV25-1384) on 12-Jun-2025 and concerns 26-years-old male patient. The patient's medical history and concomitant medication details were not provided. On 09-Jun-2025, the patient took the first dose of Vivotif (batch number: unknown) at dose two capsules, orally for typhoid immunization. On 11-Jun-2025, two days after first dose, the patient took the second dose of Vivotif (batch number: unknown) at dose two capsules orally. On an unspecified date, reported as three or four hours afterwards, the patient hade vomiting episode. At the time of the initial report, it was unknown if the patient recovered from the event of vomiting. The reporter assessed event of 'vomiting' as non-serious and possibly related to Vivotif vaccine. No further information was provided.; Reporter's Comments: A 26-year-old male received two oral doses of Vivotif for typhoid immunization on 09-Jun and 11-Jun-2025. A few hours after the second dose, he experienced a vomiting episode. His medical history and concurrent medications were not reported. Recovery status was unknown at the time of reporting. The event vomiting is listed as per CCDS v8 and USPI of Vivotif. The event vomiting assessed as related considering the plausible temporal relationship and known safety profile of the drug. The case is non-serious.; Sender's Comments: A 26-year-old male received two oral doses of Vivotif for typhoid immunization on 09-Jun and 11-Jun-2025. A few hours after the second dose, he experienced a vomiting episode. His medical history and concurrent medications were not reported. Recovery status was unknown at the time of reporting. The event vomiting is listed as per CCDS v8 and USPI of Vivotif. The event vomiting assessed as related considering the plausible temporal relationship and known safety profile of the drug. The case is non-serious.
Comments: None.